Optimizing therapy early in multiple sclerosis: An evidence-based view.

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Pharmacology

Background:

• Multiple sclerosis (MS) involves focal (lesions) and diffuse (neurodegeneration) damage.
• Diffuse damage correlates with disability progression and cognitive decline.
• First-line MS therapies may not control disease activity in all patients.

Purpose of the Study:

• To review EU-approved disease-modifying therapies for MS.
• To assess efficacy on relapses, disability, MRI, and brain volume loss.
• To evaluate early treatment optimization strategies for active MS.

Main Methods:

• Review of EU-approved disease-modifying therapies.
• Analysis of efficacy on conventional MS outcomes and brain volume loss.
• Examination of evidence for early treatment optimization.

Main Results:

• Efficacy data on disease-modifying therapies for MS outcomes are presented.
• Brain volume loss as a measure of diffuse damage is considered.
• Evidence for early treatment optimization in active MS is reviewed.

Conclusions:

• Higher-efficacy therapies may be needed for patients with inadequate response to first-line treatments.
• Targeting both focal and diffuse MS pathology is crucial for long-term control.
• An algorithm for optimal disease control in MS is proposed.